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Abstract
Background: Diabetes mellitus (DM) is a well-established risk factor for perioperative cardiovascular morbidity and
mortality in patients undergoing noncardiac surgery. However, the impact of preoperative glucose levels on
perioperative cardiovascular outcomes in patients undergoing nonemergent, major noncardiothoracic surgery is
unclear.
Methods and Results: A total of 680 patients undergoing noncardiothoracic surgery were prospectively evaluated.
Patients older than 18 years who underwent an elective, nonday case, open surgical procedure were enrolled.
Electrocardiography and cardiac biomarkers were obtained 1 day before surgery, and on days 1, 3 and 7 after
surgery. Preoperative risk factors and laboratory test results were measured and evaluated for their association with
the occurrence of in-hospital perioperative cardiovascular events. Impaired fasting glucose (IFG) defined as fasting
plasma glucose values of 100 to 125 mg/dl; DM was defined as fasting plasma glucose ≥ 126 mg/dl and/or plasma
glucose ≥ 200 mg/dl or the current use of blood glucose-lowering medication, and glucose values below 100 mg/
dl were considered normal. Plasma glucose levels were significantly higher in patients with perioperative
cardiovascular events (n = 80, 11.8%) in comparison to those without cardiovascular events (131 ± 42.5 vs 106.5 ±
37.5, p < 0.0001). Multivariate analysis revealed that patients with IFG and DM were at 2.1- and 6.4-fold increased
risk of perioperative cardiovascular events, respectively. Every 10 mg/dl increase in preoperative plasma glucose
levels was related to a 11% increase for adverse perioperative cardiovascular events.
Conclusions: Not only DM but also IFG is associated with increased perioperative cardiovascular event rates in
patients undergoing noncardiothoracic surgery.
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Background
Patients undergoing major noncardiac surgery are at high
risk of cardiovascular complications [1]. Diabetes mellitus
(DM) and hyperglycemia are risk factors for adverse peri-
operative cardiac and noncardiac events [2-5]. In patients
with known DM, the risk of atherosclerotic cardiovascu-
lar disease is increased with increasing plasma glucose
concentration. Each 1% increase in glycated haemoglobin
(HbA 1c) level was associated with a 14% increase in the
incidence of fatal and nonfatal myocardial infarction [6].
However, more recently the emphasis has shifted from
diabetes to new-onset hyperglycemia [7]. Pre-diabetes
represents a metabolic stage intermediate between nor-
mal glucose hemostasis and DM [7]. Although DM has
been recognized as an independent predictor of perio-
perative cardiovascular outcomes, the prognosis of non-
diabetic patients with impaired glucose regulation is not
clear. The relationship between preoperative glucose
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noncardiac surgical patients is not evaluated in prospec-
tive, randomized studies. This study was conducted to
elucidate the association between preoperative glucose
levels with perioperative cardiovascular events in patients
undergoing major noncardiac, nonvascular surgery.
Methods
Study design and patient population
This study was conducted during a 1-year period in 2010
at Haydarpaşa Numune Education and Research Hospital.
This hospital is a tertiary medical center in Istanbul/Tur-
key. After approval by the institutional review board, 680
consecutive patients, aged 18 yr or older, presenting for
anesthetic and noncardiothoracic, nonvascular surgery,
were included in the study. Written informed consent was
obtained from each patient before entry into the study.
Patients presenting for surgery requiring only local
anesthesia or monitored anesthesia care and day case surgi-
cal procedures were excluded. Emergent surgical cases and
the patients with an American Society of Anesthesiologists
(ASA) classification 5 (moribund, not expected to live 24 h
irrespective of operation) were also excluded [8]. The type
of surgery was classified and categorized according to the
surgical risk, determined using the American College of
Cardiology/American Heart Association (ACC/AHA) clas-
sification [9]. Intermediate-risk surgery was defined as sur-
gery with a cardiac risk of 1-5%, and included head and
neck surgery, intraperitoneal and intrathoracic surgery,
orthopaedic and prostate surgery. In our study patients,
major gastrointestinal surgery (laparotomy, advanced
bowel surgery, gastric surgery), major gynaecological can-
cer surgery (abdominal hysterectomy and oopharectomy
for cancer), and major open or transurethral urological sur-
gery (cystectomy, radical nephrectomy, total prostatect-
omy), head and neck surgery, hip or knee arthroplasty
were included. Intrathoracic surgery is not performed in
our institution.
Risk assessment, preoperative preparation and drug
therapy and postoperative follow-up were completed
according to current ACC/AHA guidelines [9]. For each
patient, preoperative risk factors of morbidity and mor-
tality, patients’ characteristics, preoperative medication
and intraoperative data were prospectively evaluated. In
the preoperative period, classification of the ASA was
used as a composite index of a patient’s general status
[8]. The Revised Cardiac Risk Index (RCRI) was used for
prediction of cardiac risk based on six prognostic factors:
high-risk type of surgery (defined as intraperitoneal,
intrathoracic, or suprainguinal vascular procedures),
ischemic heart disease, congestive heart failure, history of
cerebrovascular disease, insulin therapy for diabetes, and
preoperative serum creatinine > 2.0 mg/dl [10]. Each of
the prognostic factors assigned as one point. Anesthetic
management, monitoring, and other aspects of periopera-
tive management were at the discretion of the attending
physician.
Electrocardiography (12-lead) and cardiac biomarkers
(creatine kinase-MB and troponin I) were evaluated 1 day
before surgery, immediately after surgery, and on post-
operative days 1, 3 and 7.
All patients were fasting ≥ 8 h and were scheduled to
have their surgery in the morning. Baseline glucose mea-
surements were obtained during preoperative assessment
at a central laboratory. Blood samples were obtained
using venipuncture with minimal stasis. Glucose was
enzymatically determined using the Hexokinase method
(Boehringer, Mannheim, Germany). Information was
obtained on history of diabetes and use of blood glucose-
lowering treatment. Impaired fasting glucose (IFG), and
DM were defined according to the American Diabetes
Association (ADA) criteria [7];
￿ Patients with a known history of DM, a preoperative
fasting blood glucose level ≥ 126 mg/dl, or 2 or more
outpatient random blood glucose levels ≥ 200 mg/dl
or the current use of blood glucose-lowering medica-
tion were classified into the DM group,
￿ Impaired fasting glucose defined as fasting plasma
glucose values of 100 to 125 mg per/dl and,
￿ Fasting glucose values below 100 mg per/dl were
considered normal.
Our protocol for peri-operative blood glucose control
was based on the Alberti Regimen which involves the
use of an intravenous infusion of a pre-mixed bag of
glucose-insuline-potassium [11].
Study end-points
Patients were followed up by the consulting physician until
discharge after surgery. The perioperative cardiovascular
events were defined as the occurrence of severe arrhyth-
mias requiring treatment, cardiac death (death caused by
acute myocardial infarction, significant cardiac arrhyth-
mias, refractory congestive heart failure or as a death
occurring suddenly without another explanation), acute
heart failure, acute coronary syndrome (nonfatal acute
myocardial infarction or unstable angina), pulmonary
thromboembolism, nonfatal cardiac arrest, and cardioem-
bolic stroke. Myocardial infarction is diagnosed when the
following criteria are present: detection of a rise of tropo-
nin with at least one value above the 99th percentile of the
upper reference limit together with evidence of myocardial
ischemia as recognized by at least one of the following:
symptoms of ischemia, ECG changes of new ischemia or
development of pathologic Q waves, or new regional wall
motion abnormality according to the universal definition
of myocardial infarction [12]. This single-center cohort
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authors’ institution.
Statistical Analysis
Data were analyzed using SPSS for Windows (version
15, SPSS Inc, Chicago, Illinois). The continuous vari-
ables were expressed as mean ± standard deviation and
were compared between groups by two-tailed Student t
test. Nonparametric tests were also used when necessary
(Mann-Whitney U test). Fisher Exact (Chi-square) test
was used in comparison of categorical variables. For all
analyses, p < 0.05 was considered statistically significant.
Univariate and multivariate logistic regression analyses
were applied to determine crude and adjusted odds
ratios (ORs) and 95% confidence intervals (CIs) for the
relation between preoperative glucose levels and perio-
perative cardiovascular adverse events.
Results
Seven hundred patients were initially included in the
study. Eleven patients were excluded because of insuffi-
cient data and nine patients were excluded because of an
emergency operation. The baseline clinical and demo-
graphic characteristics of the patients with normal glu-
cose levels (n = 344, 50.6%), IFG (n = 132, 19.4%) and
DM (n = 204, 30%) are presented in Table 1, and perio-
perative characteristics are presented in Table 2. There
were no significant difference regarding the type of surgi-
cal procedure, age, gender, and body mass index between
patients with normal glucose levels, impaired glucose
regulation, and diabetes.
Prevalence of coronary/peripheral artery disease, hyper-
tension, and congestive heart failure was higher in diabetic
patients compared with patients who had impaired glucose
regulation. Patients with impaired glucose regulation had
also higher prevalence of coronary/peripheral artery dis-
ease, hypertension, and congestive heart failure compared
with normoglycemic patients. New York Heart Associa-
tion functional capacity, ASA status, and RCRI were worse
in patients with DM compared to patients with impaired
glucose regulation, and in patients with impaired glucose
regulation compared to normoglycemic patients. Preo-
perative use of beta blocker, angiotensin-converting
enzyme inhibitors, statins and aspirin was higher in
patients with DM compared to patients with impaired glu-
cose regulation, and in patients with impaired glucose reg-
ulation compared to patients with normal glucose levels.
Preoperative glucose levels and perioperative
cardiovascular events
A total of 80 patients (11.8%) had perioperative cardiovas-
cular complications (Table 3). Fifty of the patients with
DM (24.5%), 13 of the patients with impaired glucose tol-
erance (9.8%), and 17 of the patients with normal glucose
levels (5%) had adverse perioperative cardiovascular events
(p < 0.001) (Figure 1). Distribution of adverse events were
similar in patients with normal glucose levels, impaired
fasting glucose levels, and DM (p = 0.51) (Table 3). Med-
ian preoperative plasma glucose levels were significantly
higher in patients with adverse perioperative cardiovascu-
lar events compared to patients with no cardiovascular
events (124 [range 131 ± 42.5] vs 196 [106.5 ± 37.5],
p<0 . 0 0 1 ) .
The median plasma glucose levels of patients with
adverse perioperative cardiovascular events were signifi-
cantly different in the three patient groups (148 mg/dl
[84-286] in diabetic patients, 114 mg/dl [100-125] in
patients with IFG, and 86 mg/dl [73-97] in normoglyce-
mic patients, p < 0.001). Univariate analysis showed a sig-
nificant association between age, DM, IFG, coronary
artery disease, preoperative atrial fibrillation, American
Society of Anesthesiologists status, Revised Cardiac Risk
Index and perioperative cardiovascular events. On multi-
variate logistic regression analysis DM and IFG remained
as significant variables associated with perioperative car-
diovascular complications. Patients with impaired glucose
regulation and DM were at 2.1-fold (adjusted OR 2.1 and
95% CI 0.99-4.49; p < 0.04), and 6.4-fold (adjusted OR
6.4 and 95% CI 3.57-11.48; p < 0.001) increased risk for
perioperative cardiovascular events, respectively. Every
10 mg/dl increase in preoperative plasma glucose levels
was related to a 11% increase for adverse perioperative
cardiovascular events.
Discussion
Our study demonstrated that increased preoperative glu-
cose levels are associated with adverse perioperative car-
diovascular events in patients undergoing major
noncardiac surgery. Not only DM, but also impaired
glucose regulation was associated with an increased inci-
dence of perioperative cardiovascular complications.
Recent data indicate that postprandial hyperglycemia or
even impaired glucose tolerance may predispose to pro-
gression of atherosclerosis and cardiovascular events [13].
However, the prognostic role of impaired glucose tolerance
in noncardiac surgery patients is not fully elucidated.
Although DM has been recognized as an independent pre-
dictor of perioperative cardiovascular complications in
patients undergoing noncardiac surgery only a few studies
take preoperative glucose levels into account. The associa-
tion between preoperative glucose levels and perioperative
cardiac and noncardiac complications is, however, contro-
versial. Velanovich [14] found that an abnormal preopera-
tive glucose value was an independent predictor of
postoperative bleeding, whereas McKee and Scott demon-
strated the association of postoperative complications with
any preoperative laboratory abnormalities [15]. Dzankic
et al. evaluated the prevalence and predictive value of
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patients ≥ 70 yr old who were undergoing noncardiac sur-
gery [16] Abnormal hemoglobin, creatinine, and glucose
values were not predictive of postoperative adverse out-
comes. Only ASA classification and surgical risk were sig-
nificant independent predictors of postoperative adverse
outcomes.
Feringa et al. investigated whether impaired glucose reg-
ulation and elevated glycated HbA 1c levels are associated
with increased cardiac ischaemic events in vascular sur-
gery patients [17]. They have measured baseline glucose
and HbA 1c levels in 401 vascular surgery patients. Using
subjects with normal glucose levels as the reference cate-
gory, multivariate analysis revealed that patients with
impaired glucose regulation and diabetes were at 2.2- and
2.6-fold increased risk of ischaemia, 3.8- and 3.9-fold for
troponin release, 4.3- and 4.8-fold for 30-day cardiac
events, and 1.9- and 3.1-fold for long-term cardiac events.
Patients with HbA 1c > 7.0% were at 2.8-fold, 2.1-fold,
5.3-fold and 5.6-fold increased risk for ischaemia, troponin
release, 30-day and long-term cardiac events, respectively.
This study demonstrated the value of preoperative glucose
and HbA1c in defining perioperative and long-term risk in
vascular surgery patients.
Impaired glucose regulation is a term that refers to
blood glucose levels that are above the normal range but
are not high enough for the diagnosis of DM [7]. This
term is used to describe the presence of IFG and/or
impaired glucose tolerance, which are intermediate states
of abnormal glucose regulation that exist between normal
blood glucose levels and DM. Both IFG and impaired
glucose tolerance are risk factors for the subsequent
development of both DM and cardiovascular disease
[18-21]. However, it is unclear whether IFG or impaired
glucose tolerance are independent risk factors in the
development of cardiovascular complications in patients
undergoing noncardiac surgery.
Dunkelgrun et al. showed that the prevalence of
undiagnosed impaired glucose tolerance and DM is high
in vascular surgery patients. Of 404 patients without his-
tories of impaired glucose tolerance and DM, 26% had
impaired glucose tolerance and 11% diabetes [22].
Furthermore, the presence of DM significantly predicted
the risk for perioperative cardiac ischemia (OR = 3.2,
95%CI 1.3-8.1). Kuijk et al. also showed that the patients
with impaired glucose tolerance had adverse prognosis
even worse than that of patients with DM in vascular sur-
gery patients [23]. Noordzij et al. undertook a retrospec-
tive case-control study among 904 cases and 1247
controls who underwent noncardiac, nonvascular surgical
procedures in the Erasmus MC [24]. In this study, they
showed that prediabetes glucose levels had a 3-fold
Table 1 Baseline clinical and demographic characteristics
All patients
(n = 680)
Normal glucose
(n = 344)
Impaired fasting glucose
(n = 132)
Diabetes mellitus
(n = 204)
P value
Age 65,4 ± 14 62,5 ± 15,6 68,9 ± 11,9 67,8 ± 11,3 0,328
Male 358(52,6) 173(50,3) 66(50) 119(58,3) 0,151
Body mass index 28,3 ± 12,2 27,6 ± 5,5 27,4 ± 3,8 30,2 ± 20,8 0,146
ASA status 1 117(17,2) 88(25,6) 18(13,8) 0 < 0,001
2 344(50,6) 182(52,9) 76(57,6) 97(47,5)
3 166(24,4) 54(15,7) 27(20,5) 85(41,7)
4 53(7,8) 20(5,8) 11(8,3) 22(10,8)
Hypertension 375(55,1) 152(44,2) 79(59,8) 144(70,6) < 0,001
Current smoking 100(14,7) 51(14,8) 17(12,9) 32(15,7) 0,66
Coronary artery disease 182(26,8) 64(18,6) 29(22) 89(43,6) < 0,001
Heart failure 69(10,1) 20(5,8) 16(12,1) 33(16,2) < 0,001
History of CVA 65(9,6) 24(7) 16(12,1) 25(12,3) 0,068
Atrial fibrillation 82(12,1) 43(12,5) 13(9,8) 26(12,7) 0,683
NYHA functional class 1 426(62,6) 233(67,7) 85(64,4) 108(52,9) < 0,001
2 235(34,6) 108(31,4) 45(34,1) 82(40,2)
3 18(2,6) 3(0,9) 2(1,5) 13(6,4)
4 1(0,1) 0(0) 0(0) 1(0,5)
Revised cardiac risk index 0 95(14) 63(18,3) 19(14,4) 13(6,4) < 0,001
1 313(46) 187(54,4) 57(43,2) 69(33,8)
2 195(28,7) 75(21,8) 45(34,1) 75(36,8)
3 70(10,3) 19(5,5) 10(7,6) 41(20,1)
4 7(1) 0(0) 1(0,8) 6(2,9)
Abbreviations: ASA = American Society of Anesthesiologists; CVA = cerebrovascular accident: NYHA = New York Heart Association. Values are given as mean ±
SD or number (percentage).
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levels had a 4-fold increased cardiovascular mortality
risk. In subjects with prediabetes glucose levels, a con-
tinuously increasing risk of perioperative mortality was
observed along with increasing glucose concentration
and each 1 mmol/l increase was associated with a 19%
risk increase for mortality. The results of this study is
important to show that prediabetes glucose levels in
patients without a history of diabetes were also associated
with increased perioperative cardiovascular death.
Although our study differs from the Noordzij et al. study
with its prospective design, we have also showed that the
patients with impaired glucose regulation undergoing
noncardiac, nonvascular surgery are at risk for develop-
ing cardiovascular complications.
Recently, Hatzakorzian et al. observed fasting hyper-
glycemia in > 25% of presumably non-diabetic patients
presenting for elective surgery [25]. However, they have
not evaluated the significance of preoperative IFG on
peri-operative cardiovascular outcomes. In the current
Table 2 Perioperative characteristics
All patients
(n = 680)
Normal glucose
(n = 344)
Impaired fasting glucose
(n = 132)
Diabetes mellitus
(n = 204)
P value
Beta-blocker 157(23,1) 61(17,7) 33(25) 63(30,9) 0,002
Calcium inhibitor 99(14,6) 51(14,8) 16(12,1) 32(15,7) 0,651
ACE inhibitor 180(26,5) 75(21,8) 37(28) 68(33,3) 0,011
Furosemid 21(3,1) 10(2,9) 7(5,3) 4(2) 0,216
Thiazid 22(3,2) 10(2,9) 4(3) 8(3,9) 0,801
Sprinolactone 20(2,9) 8(2,3) 6(4,5) 6(2,9) 0,439
Aspirin 146(21,5) 47(13,7) 27(20,5) 72(35,3) < 0,001
Statin 67(9,9) 17(4,9) 7(5,3) 43(21,1) < 0,001
Digoxin 25(3,7) 10(2,9) 7(5,3) 8(3,9) 0,450
Anticoagulant 31(4,6) 11(3,2) 9(6,8) 11(5,4) 0,188
ARB 60(8,8) 25(7,3) 9(6,8) 26(12,7) 0,061
General 288(42,4) 143(41,6) 58(43,9) 87(42,6)
Urology 131(19,3) 70(20,3) 25(18,9) 36(17,6)
Plastics 32(4,7) 17(4,9) 7(5,3) 8(3,9)
Type of surgery Gynecological 33(4,9) 18(5,2) 5(3,8) 10(4,9) 0,724
Orthopedic 160(23,5) 77(22,4) 35(26,5) 48(23,5)
Ophthalmologic 9(1,3) 4(1,2) 2(1,5) 3(1,5)
Neurological 19(2,8) 11(3,2) 1(0,8) 7(3,4)
Ear/nose/throat 8(1,2) 4(1,2) 2(1,5) 2(1)
Triglyceride (mg/dl) 143,4 ± 75,9 141,3 ± 85,5 137,9 ± 55,8 150,5 ± 69,4 0,182
High density lipoprotein (mg/dl) 45,6 ± 17,4 46,4 ± 18,4 45 ± 15,7 44,6 ± 16,7 0,323
Low density lipoprotein (mg/dl) 108,8 ± 32,7 107,4 ± 32,1 114,3 ± 36,3 107,6 ± 31 0,148
Creatinine (mg/dl) 1,2 ± 1,4 1,2 ± 1,6 1,2 ± 1,2 1,2 ± 1,1 0,163
Fasting glucose (mg/dl) 109,4 ± 38,7 86,8 ± 8,6 109,6 ± 7,3 147,6 ± 50,1 < 0,001
Abbreviations: ACE = Angiotensin-converting enzyme inhibitor; ARB = angiotensin II-receptor blocker. Values are given as mean ± SD or number (percentage).
Table 3 Adverse perioperative cardiovascular events
All patients
(n = 680)
Normal glucose
(n = 344)
Impaired fasting glucose
(n = 132)
Diabetes mellitus
(n = 204)
P value
PCE No 600(88,2) 327(95) 119(90,2) 154(75,5) < 0,001
Yes 80(11,8) 17(5) 13(9,8) 50(24,5)
Acute coronary syndrome 24(30) 6(35,3) 6(46,2) 12(24)
Severe arrhythmia 12(15) 2(11,8) 1(7,7) 9(18)
Distrubition of PCE Nonfatal cardiac arrest 5(6,3) 1(5,9) 1(7,7) 3(6) 0,512
Cardiovascular death 5(6,3) 1(5,9) 0(0) 4(8)
Cardioembolic stroke 10(12,5) 1(5,9) 2(15,4) 7(14)
Pulmonary embolism 7(8,8) 4(23,5) 0(0) 3(6)
Acute heart failure 17(21,3) 2(11,8) 3(23,1) 12(24)
Abbreviations: PCE = Perioperative cardiovascular adverse event. Values are given as mean ± SD or number (percentage)
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cardiac surgery had fasting blood glucose levels compa-
tible with IFG, and 30% of the patients had DM.
A l t h o u g ht h ep r e v a l e n c eo fD Ma n dI F Gi sh i g h e rt h a n
the world wide [26], our population consisted of patients
with a mean age of 65 years and undergoing surgery in
a tertiary center.
Study Limitations
Our study did not address the question of whether
treatment of hyperglycemia may reduce the high mor-
bidity and mortality associated with hyperglycemia in
patients with IFG or DM. The second limitation of our
study is that we were not able to determine the percen-
tage of patients with latent DM because of the lack of
hemoglobin A1C testing and the lack of follow-up after
discharge. Stress- induced hyperglycemia, could have
p a r t l yc o n t r i b u t e dt oe l e v a t e df a s t i n gb l o o dg l u c o s e
levels. However, it was not possible to differentiate
between stress-induced perioperative hyperglycemia and
blood glucose rise associated with preexisting glycemic
disease.
Conclusions
In conclusion, this study shows that impaired glucose
regulation and DM are risk factors for perioperative car-
diovascular events in noncardiac surgery patients. The
results of our study suggest that screening for glucose
dysregulation in these patients should be part of stan-
dard preoperative testing. However, the value of screen-
ing for dysglycaemia and the benefits of aggressive
glucose management require further prospective, rando-
mized studies.
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